Supporting Information

A Fluorescent Transport Assay Enables Studying AmpG Permeases Involved in Peptidoglycan Recycling and Antibiotic Resistance.

G. Evan Perley-Robertson,^{†,} Anuj K. Yadav,^{†,} Judith L. Winogrodzki,[‡] Keith A. Stubbs,§

5 Brian L. Mark,[‡] and David J. Vocadlo^{†,*}

[†]Department of Chemistry, Simon Fraser University, Burnaby, British Columbia, V5A 1S6, Canada

[‡]Department of Microbiology, University of Manitoba, Winnipeg, Manitoba, R3T 2N2, Canada


[§]School of Chemistry and Biochemistry, University of Western Australia, Crawley,
 Western Australia 6009, Australia

*Corresponding author: <u>dvocadlo@sfu.ca</u>

Contents


	Supporting Figures	2
15	NMR Spectra	8
	Supporting Methods	12
	Supporting References	17

20 Supporting Figures




Supplementary Figure 1. Neither whole cell *Ec*BW nor *Ec*BW*AampG* are capable of internalizing probe 9, regardless of incubation time. Fluorescence observed for native

*Ec*BW and *Ec*BW Δ *ampG* bacteria after incubation in the presence (+) or absence (-) of probe **9**. Error bars represent the standard error of the mean.




Supplementary Figure 2. Three washes were sufficient to remove the vast majority of excess NBD-Gic or probe 9. (A) Supernatant fluorescence after one to three washes


of *Ec*BW or *Ec*BW Δ *ampG* spheroplasts which were incubated with (+) or without (-) NBD-Glc or probe **9**. (**B**) Supernatant fluorescence after one to four washes of *Ec*MG Δ *ampG* spheroplasts bearing the empty vector, or a plasmid expressing V5 His₆ tagged *Pa*-AmpG or *Pa*-AmpP, which were incubated with (+) or without (-) NBD-Glc or probe **9**. Error bars represent the standard error of the mean. Data plotted on a logarithmic y-axis.




Supplementary Figure 3. EcBW spheroplasts exhibit linearity in the initial uptake of probe 9, the amount of extravesicular probe remains constant, and a Lineweaver-Burk plot of the data in Figure 3 gives a *K*_M value similar to that found by non-linear regression. A: Time course for the uptake of probe 9 into EcBW spheroplasts. A line of best fit is indicated for the first five time points, up to and including 40 90 min, to indicate the approximately linear rate of probe internalization over this period. **B**: Supernatant fluorescence from time course remains constant, indicating that only a small amount of probe 9 is internalized. Error bars represent the standard error of the mean. C: The five highest concentrations from Figure 3 were plotted on reciprocal x- and y-axes, and the $K_{\rm M}$ was determined from the negative reciprocal of the x-intercept.



Supplementary 4. Monosaccharides GlcNAc and anhMurNAc have no impact on the AmpG-mediated transport of probe 9. Fluorescence observed for *Ec*BW spheroplasts after incubation with a range of GlcNAc or anhMurNAc concentrations in the presence of probe 9. This experiment was carried out in parallel with the competitive assay which used GlcNAc-anhMurNAc, indicating the viability of the spheroplasts.



Supplementary Figure 5. V5 His₆ tagged *Pa*-AmpG and *Pa*-AmpP expression is
saturated at 0.2% inducer, and both proteins are targeted to the membrane under spheroplasting conditions. (A) The expression of both *Pa*-AmpG and *Pa*-AmpP depends on the concentration of inducer (L-arabinose). It should be noted that when the cells are grown in LB medium, the expression levels of *Pa*-AmpG and *Pa*-AmpP become saturated at 0.2% arabinose as shown. We therefore chose 0.2% inducer in LB-grown cultures for the purposes of isolating spheroplasts. (B) Membrane fractionation of *Ec*MGΔ*ampG* spheroplasts expressing *Pa*-AmpG (G) or *Pa*-AmpP (P) indicates that the proteins are properly targeted to the inner membrane



- Supplementary Figure 6. AmpG knockout spheroplasts (EcMGΔampG) which were transformed with an empty vector, Pa-AmpG, or Pa-AmpP, are all able to internalize NBD-Glc, indicating they are comparably viable. (A) DIC (left), fluorescence (center), and overlay (right) images of EcBWΔampG spheroplasts transformed with the empty vector (pBAD322-V5His-Km, top), or the V5His tagged proteins Pa-AmpG (pBAD-Pa-
- 70 AmpG-V5His-Km, center) or Pa-AmpP (pBAD-Pa-AmpP-V5His-Km, bottom) after incubation with NBD-Glc. A 20 µm bar is included for scale. An excitation wavelength of 470 nm was used.

-2000	 	- 1800	H -1700		-1600		-1500		- 1400	1300		-1200		-1100	-	-1000	ح -	00%		5	-700	-600	5	-500	-400	 - 300	-200	-100	-	> 	100
	Válue	AY-DS-amide-11	Bruker BioSpin GmbH	nstmu	spect	MeOD	298.0	zg30	1D	16	23	2.0000	8.4000	3.6351	ncy 600.33	9014.4	-917.2	1H	32768	65536											
	Parameter	1 Title	2 Origin		4 Spectrometer			7 Pulse Sequence	8 Experiment	9 Number of Scans	10 Receiver Gain	11 Relaxation Delay	12 Pulse Width	13 Acquisition Time	14 Spectrometer Frequency 600.33	15 Spectral Width	16 Lowest Frequency	17 Nucleus	18 Acquired Size	19 Spectral Size										=	- -81.E
								=																						=	€ [_] 1⁄£.£
																															r 16 7 r 20 7 r 07 1 - 90 1 - 707 1 - 90 1 - 767 7 - 752 1 - 60 1 - 60 1 - 61 1 - 80 1 - 90 1 - 9
																															E-06.1 E-02.2
										I	NCbz	T																			
								_		11					NHAC NHAC	NHAC													Y	-	E-07'S
										_					e e	2															

75 NMR Spectra

-15000	-	-13000		-12000	-11000	, , ,	-10000			-2000		-8000)))		-7000		-6000	-	-5000	-4000	-3000	-2000	-1000		0-	-		
	Value	AY-DS-amide-11	Bruker BioSpin GmbH	nmsu	798 0	5dbz	1D	1024	2580	2.0000	11.3000	0.9088	ncy 150.95	36057.7	-2721.6	13C	32768	65536							weis fearright in die providielite weische Arbuittelich under		-	10 0
87.81 —	Parameter		5	Owner	Solvent	Pulse Sequence	8 Experiment	er of Scans	10 Receiver Gain	11 Relaxation Delay	Width	13 Acquisition Time	14 Spectrometer Frequency 150.95	15 Spectral Width	16 Lowest Frequency	sus	18 Acquired Size	tral Size							No.		-	30 20
26'68∼ 6L'1⊅∽			2 Origin		Termeral		8 Expe	9 Num	10 Rece	11 Relay	12 Pulse Width	13 Acqu	14 Spec	15 Spec	16 Lowe	17 Nucleus	18 Acqu	19 Spectral Size							WATER COLORING IN COLORING		-	40
20'6t							_	_														-					-	50
80 25																						 			United States in the second states		-	70 60
929 259 259 259 252 972 972 972 972 972 972 972 97																									payor a survey with the polynomial of particular		-	90 80
¹⁷⁰¹ >																									and the second structure of th		-	110 100
							ŻI	=													-	 			mental history of the second state		-	130 120
:'8EL —						T2		0-	201	NHAC		0												_			-	140
·851 —									HO	HOMON	5	NHAC												_			-	160 150
7°821~ 3°721~ 0°921~																							_		utrate/whyten/utrant/		-	180 170

	-2500		- 2000	-1500	-1000	- 500	. 0	
	Válue AY-2-1	Bruker BioSpin GmbH nmrsu spect	MeOD 295.0 2930 10 23 23 2000	8.4000 3.6351 ncy 600.33 9014.4	-916.0 1H 32768 65536			
±2.1.36	Parameter 1 Title	2 Origin 3 Owner 4 Spectrometer	 5. Solvent 6. Temperature 7. Pulse Sequence 8. Experiment 9. Number of Scans 10. Receiver Gain 11. Relaxation Delay 	12 Pulse Wkth 8. 4000 13 Acquisition Time 3. 6351 14 Spectrometer Frequency 600 33 15 Spectral Wkth 9014, 4	16 Lowest Frequency 17 Nucleus 18 Acquired Size 19 Spectral Size			3.17-€ 1.5 1.0 0.5
107 507 787								5.5 285-T
242 522 522 522 522 522 522 522								H-9-1
1E.2			O NH2					€.0 5.5 6.0 5.5 6.0 7.5 6.0
6.61				> ZI >				7.0 6.5
00.0					NHAC			8.0 7.5
80.8—				HOV				

-110000	-100000		-90000	- 1	-80000			-7000	0000		6000	00000			-50000			-40000	 -30000	 -20000	-	00001-	0-	 10000	
6751~	Value	AY-2-1 Bruker BioSpin GrrbH	nmrsu	spect	MEOU 295.0	0.062 ZODA	1D	3000	2580	2.0000	11.3000	0.9088	ency 150.95	36057.7	-2722.2	13C	32768	65536					 אן גרוארון אראריגעריינעריין אראריגעריינעריין אראריערייערייערייערייעריעריעריעריער		- 0
	Parameter	Title Origin	Owner	Spectrometer	Solvent Termerature	Pulse Sectioner	Experiment	9 Number of Scans	10 Receiver Gain	11 Relaxation Delay	12 Pulse Width	13 Acquisition Time	14 Spectrometer Frequency 150.95	15 Spectral Width	16 Lowest Frequency	17 Nucleus	18 Acquired Size	19 Spectral Size				==	 all marine the second		30 - 20
		5 H		4 r 7 S			2	۲ ۵	10 Re	11 Re	12 PL	13 Ac	14 Sp	15 Sp	16 Lo	17 N	18 Ac	19 Sp					humber		- 4
00'67 58'67 58'67	_	_																	 _	-					- 2
91ZS—																							 -		- 3
25 63 25 63 25 20 25 20 20																							man manual and and		- 02
08'52 12'22 20'82 91'62																									90 80
68.101 20.201 20.201						NH	2	Hos						_									In particular to the second property of the second		- 01
82'011																						-	 		0 110
59 ^{.921} >							, о= н	$\langle \rangle$	Ξ														 many		130 120
								\rangle		1	2														. 140
67.051 25.751 88.951 ~									- L		Ч Ч			NHAc								-	 manufundance		0 150
∠l' b 9l—								,				PH	POH										 and the second second		- 16
57.671 26.471 66.271																						-	 many		180 170

80 Supporting Methods

Characterization of Key Chemical Compounds. Compound 8. Rf 0.6 (6:3:1 EtOAc:MeOH:H2O); HRMS (ESI-TOF) m/z 655.2823 (655.2821 calcd for C29H43N4O13⁺, [M+H]⁺); ¹H-NMR (600 MHz, MeOD) δ 7.33 – 7.25 (m, 5H), 5.24 (s, 1H), 5.04 (q, J = 12.5, 2H), 4.54 (d, J = 5.4, 1H), 4.45 (d, J = 8.4, 1H), 4.14 (d, J = 7.5, 1H),4.05 (q, J = 6.8, 1H), 3.97 (s, 1H), 3.87 (dd, J = 11.9, 1.9, 1H), 3.79 (s, 1H), 3.76 - 3.70 85 (m, 1H), 3.68 - 3.63 (m, 2H), 3.47 (s, 1H), 3.41 (dd, J = 10.5, 8.2, 1H), 3.37 - 3.33 (m, 1H), 3.41 (dd, J = 10.5, 8.2, 1H), 3.41 (dd, J = 10.5, 8.2), 3.411H), 3.32 (s, 1H), 3.31–3.30 (m, 1H), 3.25 (dd, J = 9.7, 3.8, 3H), 2.02 (s, 3H), 2.00 (s, 3H), 1.32 (d, J = 6.8, 3H); ¹³C-NMR (151 MHz, MeOD) δ 176.05, 174.90, 173.52, 158.98, 138.35, 129.53, 129.04, 128.96, 102.05, 101.88, 79.61, 78.26, 77.58, 75.41, 75.32, 74.65, 72.07, 67.53, 65.84, 62.69, 57.14, 49.05, 41.24, 39.98, 23.50, 22.68, 18.83. 90

GlcNAc-anhMurNAc-AF350 **9**. R_f 0.6 (3:2:1 EtOAc:MeOH:H2O); HRMS (ESI-TOF) m/z 816.2601 (816.2604 calcd for C33H46N5O17S⁺, [M+H]⁺); ¹H-NMR (600 MHz, MeOD) δ 8.03 (s, 1H), 6.55 (s, 1H), 5.25 (s, 1H), 4.41 – 4.39 (m, 2H), 4.01 (q, J = 6.7, 1H), 3.94 (d, J = 7.5, 1H), 3.87 – 3.81 (m, 2H), 3.66 (ddd, J = 17.4, 15.6, 7.1, 3H), 3.57 – 3.51 (m, 4H), 3.44 (dd, J = 11.7, 6.8, 2H), 3.38 – 3.31 (m, 2H), 3.29 (d, J = 0.6, 4H), 2.37 (s, 3H), 1.98 (s, 4H), 1.96 (s, 3H), 1.30 (d, J = 6.7, 4H); ¹³C-NMR (151 MHz, MeOD) δ 176.04, 174.97, 173.40, 173.30, 164.22, 156.43, 152.58, 150.34, 126.85, 126.70, 115.68, 110.83, 102.20, 102.07, 101.94, 79.21, 78.12, 77.26, 75.85, 75.35, 74.78, 72.06, 65.83, 62.68, 57.21, 49.05, 40.12, 39.87, 35.41, 23.49, 22.67, 18.65, 15.54.

Bacterial Strains and Culture Conditions. For routine cloning and plasmid propagation, DH5α (F⁻ Φ80*lac*ZΔM15 Δ(*lac*ZYA-*arg*F) U169 *rec*A1 *end*A1 *hsd*R17(r_k⁻, m_k⁺) *phoA sup*E44 *thi*-1 *gyr*A96 *rel*A1 λ⁻) or TOP10 (F- *mcrA* Δ(*mrr-hsd*RMS-*mcr*BC) Φ80*lac*ZΔM15 Δ *lac*X74 *rec*A1 *ara*D139 Δ(*araleu*)7697 *gal*U *gal*K *rps*L (StrR) *end*A1 *nup*G) were used as hosts. *E. coli* BW25113 (CGSC No. 7636) and MG1655 (CGSC No. 6300) were utilized for gene modification and was obtained from the Coli Genetic Stock Centre (Yale University, New Haven, CT, USA). *Pseudomonas aeruginosa* PAO1 was used for chromosomal DNA isolation and was generously provided by Dr. A. Oliver (Instituto Universitario de Investigación en Ciencias de la Salud (IUNICS), Palma de Mallorca, Spain). If not otherwise stated, cells were grown aerobically in LB medium (10

- g/L tryptone, 5 g/L yeast extract, 5 g/L sodium chloride) with the following additions: 150 μg/mL ampicillin, 35 μg/mL kanamycin and/or 35 μg/mL chloramphenicol and 0.2% (w/v) arabinose. For β-lactamase assays, the cells were grown in M9CA supplemented with 1 μg/mL thiamine, 50 μg/mL uracil, 35 μg/mL chloramphenicol, 70 μg/mL kanamycin, 0.5% (v/v) glycerol and arabinose at the indicated concentration.
- 115 Deletion of Ec-AmpG from the Chromosome of BW25113 and MG1655. Wildtype *E. coli* BW25113 (CGSC No. 7636) and its isogenic *∆ampG790::kan* derivative (CGSC No. 8587, Keio Collection No. JW0423-1, Baba et al., 2006) were obtained from the Coli Genetic Stock Center. The kanamycin resistance gene of the mutant was eliminated via recombination between the flanking FRT sites using FLP recombinase (Datsenko et al., 2000) supplied by the chloramphenicol and ampicillin 120 resistant, temperature-sensitive plasmid, pCP20 (Cherepanov et al., 1995). This plasmid was subsequently cured by growth at 42 °C and the strain was tested for loss of all antibiotic resistance determinants. Chromosomal deletion of the ampG gene in E. coli MG1655 (CGSC No. 6300) was carried out using the strategy as described (Baba et al.,
- 125 2006). Briefly, PCR products were amplified using primers EC∆AMPGF: 5'-GATTACTACAGCTAAATAATATTTACAGATTACGTCAGATGCGTTTTTCGattccggggat ccgtcgacc-3' and EC∆AMPGR: 5'-TTAATTTCTGCCCTCTGGCCCGGTGCAAGCCGG-GCCTGTAGACGCCCATGtgtaggctggagctgcttcg-3' and Phusion High Fidelity DNA polymerase as specified by the manufacturer. These primers were designed to have 20 nucleotide C-terminal ends for priming the FRT sites flanking the kanamycin resistance
- cassette in pKD13² (lower case letters) and 50 nucleotide ends homologous to the regions upstream and downstream of the targeted gene deletion (upper case letters).Chromosomal integrants were selected as kanamycin resistant colonies after electroporation of the PCR product into MG1655 harbouring the ampicillin resistant λ Red expression plasmid, pKD46 (Datsenko et al., 2000). The kanamycin resistance gene was 135 then eliminated using pCP20 (Cherepanov et al., 1995) as described above. The presence of the null deletion in both strains was verified by PCR amplification using the 5'-GACAACCATCCCAAACTTTTATTGTATTTCCTG-3' primers ECAMPGF: and ECAMPGR 5'- CGTCACCGTAAGCATTAATGGTGC-3'.

Construction of pBAD-Pa-AmpG-Km and pBAD-Pa-AmpP-Km. Phusion High 140 Fidelity DNA polymerase was used to PCR amplify the ampG (Pa4393) and ampP (Pa4218) ORFs utilising chromosomal DNA isolated from Pseudomonas aeruginosa PAO1 as described (Chen et al., 1995). Primers used for amplification were PA4393F: 5'-GATATAgaattcACCATGACTCAGCAATCCTGGCGAGAG-3' (an introduced EcoR1 site is in lower-case letters) and PA4393R: 5'-CTATATaagcttTCAGTGCTGCTCG-145 GCGTTCTG-3' (an introduced HindIII site is in lower case letters), and PA4218F: 5'-GATATAgaattcACCATGCTTGAGCTGTAC-3' (an introduced EcoR1 site is in lower-case letters) and PA4218R: 5'-CTATATaagcttTCAGGCCTCTTCCGCCCG-3' (an introduced HindIII site is in lower-case letters), respectively. The purified PCR products were then directionally cloned into pBAD322-Km (Cronan, 2006) under the arabinose-inducible, 150 glucose-attenuable P_{BAD} promoter, as EcoR1/HindIII fragments and the fidelity of the inserts was confirmed by DNA sequencing at the Toronto Hospital for SickKids, Centre for Applied Genomics, DNA Sequencing/Synthesis Facility.

Construction of pBAD-Pa-AmpG-V5His-Km and pBAD-Pa-AmpP-V5His-Km.

155 Initially, a fragment containing the C-terminal V5 epitope and six histidine tag, together with the downstream *rrn*B T₁ and T₂ transcriptional terminators was amplified by PCR utilizing pBAD-TOPO/lacZ/V5-His plasmid DNA as a template. Primers V5HISF: 5'-GATATAaagcttGGTAAGCCTATCCCTAAC-3' (an introduced HindIII site is in lower-case letters) and V5HISR: 5'-CTATATtcatgaGAGTTTGTAGAAACGCAAAAAG-3' (an introduced BspH1 site is in lower-case letters) were used, as well as Phusion High Fidelity 160 DNA polymerase under the reaction conditions as suggested by the manufacturer. The resulting purified PCR product was then cloned into pBAD322-Km (Cronan, 2006) expression vector as a HindIII/BspH1 fragment yielding the pBAD322-V5His-Km construct. pBAD-Pa-AmpG-V5His-Km and pBAD-Pa-AmpP-V5His-Km were generated essentially as described above, but the reverse primers used for PCR amplification 165 (AMPGV5HISR: 5'-CTATATaagcttGTGCTGCTCGGCGTTCTG-3' and AMPPV5HISR: 5'-CTATATaagcttGGCCTCTTCCGCCCG-3') were designed to eliminate the native stop codon of both ORFs to preserve reading through the C-terminal V5 epitope and six histidine tags provided by the pBAD322-V5His-Km vector. DNA sequencing at the

170 Toronto Hospital for SickKids, Centre for Applied Genomics, DNA Sequencing/Synthesis Facility, confirmed the fidelity of all inserts.

Western Blot Analysis. 50 μg of total protein in a final volume of 20 μL was mixed with 20 μL of standard 2X loading buffer and heated at 37 °C for 15 min. Proteins were resolved on 12% polyacrylamide gels and transferred onto Immobilin-P PVDF Western blotting membrane using the Bio-Rad Mini-Trans-Blot Electrophoretic Wet Transfer Cell according to the manufacturer's instructions. The membranes were blocked overnight at 4 °C in 5% skim milk powder dissolved in 1X TBS (2.4 g/L Tris, 8.8 g/L NaCl, pH 7.4), then washed twice in 1X TBS for 5 min, prior to incubation in the presence of mouse α-V5-HRP conjugate at a dilution of 1:5000 in 1% skim milk powder dissolved in 1X TBS for 1 hr at room temperature. The blots were then rinsed four times in 1X TBS containing 0.05% Tween-20 for 10 min at room temperature and immunoreactive proteins were detected using Luminata Forte Western HRP Chemiluminescent substrate, as recommended by the supplier. Fluorchem 8900 was used to obtain the resulting signal.

Dose-dependent expression of V5His tagged Pa-AmpG and Pa-AmpP. Overnight cultures of *Ec*MG*AampG* transformed with the pBAD-*Pa*-AmpG-V5His-Km or 185 pBAD-Pa-AmpP-V5His-Km were inoculated, one in fifty, into 3.0 mL of the LB containing 35 µg/mL kanamycin, and grown at 28 °C until the optical density at 600 nm reached approximately 0.4. To induce expression, L-arabinose was added at the indicated concentration and the cultures were grown at 28 °C for an additional three hours. The cells were then pelleted by centrifugation at 6,000 rcf at 4 °C for 5 min, washed once with 190 PBS, resuspended in lysis buffer containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% Triton-X-100, 100 µg/mL lysozyme, 50 µg/mL DNase, 0.1 mM PMSF and 0.5 mM TCEP, then mixed by end-over-end rotation for 1 hr at 4 °C. The cellular debris was subsequently removed by centrifugation at 12,000 rcf at 4 °C for 30 min, and the supernatants, which contained solubilized membranes, were analysed by Western blot analysis as described 195 above. Protein concentrations were quantified by the Bradford assay using bovine gamma globulin as the standard.

Spheroplast fractionation. Approximately 60 mg of spheroplasts were collected by centrifugation at 2,000 rcf at 4 °C for 5 min, washed once in dilution solution containing

- 0.5 mM TCEP and 0.1 mM PMSF, resuspended in the same buffer, supplemented with 200 1% Triton-X-100 and 0.1% SDS, then mixed by end-over-end rotation for 1 hr at room temperature. The suspensions were then pelleted by two consecutive spins at 16,000 rcf at 4 °C for 20 min and the resulting supernatants containing solubilized membrane protein were retained. The final pellets, representing the insoluble fraction, were resuspended in 205 300 μ L of dilution solution, sonicated three times at 50% duty cycle, six second bursts, with 10 seconds of incubation on ice between each burst. Western blot analysis was performed as described above. The Protein concentration of all fractions was quantified by the Bradford assay using bovine gamma globulin as the standard.
- Transport of Probe 9 by Native EcBW and EcBW∆ampG E. coli. Wild-type or isogenic *ampG* BW25113 *E. coli* (*Ec*BW or *Ec*BW∆*ampG*) were grown until the OD600 210 reached ~ 0.5 - 0.6, as described in the 'Preparation of Spheroplasts' portion of the Materials and Methods. To 1 L of LB, preheated to 37 °C, was added 120 mL of OD600 0.5 - 0.6 culture. The cells were grown aerobically at 37 °C for 1 hr, centrifuged at 3000 rcf at 4 °C for 10 min, and resuspended to homogeneity in dilution solution to a 215 concentration of 0.25 g/mL. The resuspended bacteria was stored at 4 °C. The next day 200 μ L of 0.25 g/mL *Ec*BW or *Ec*BW Δ *ampG* was added to microcentrifuge tubes, and the solution was brought up to 250 µL with dilution solution. The experiment was initiated by the addition of 100 µL of 175 µM probe 9. Blanks were prepared in which dilution solution was added in place of probe 9. Tubes were mixed by inversion several times, then incubated for 1 or 3 hr at 25 °C in the dark using a digital heatblock. Final reaction 220 conditions were: 350 µL; 50 µM probe 9, and 0.15 g/mL E. coli. Post-experiment washing and fluorescence quantitation was performed as described in the Materials and Methods.

Time Course of Probe 9 Uptake by EcBW spheroplasts. The experiment was carried out in duplicate using EcBW spheroplasts. In brief, 50 µL of 0.25 g/mL spheroplasts were added to microcentrifuge tubes, followed by the addition of 50 µL of 100 µM probe 9 in dilution solution, beginning with those tubes corresponding to the longest time points. Blanks contained dilution solution in place of probe 9. The tubes were inverted several times to mix, and were incubated for 0, 5, 10, 30, 60, 90, 120, and 240 minutes at 25 °C in the dark using a digital heatblock. Final reaction conditions were: 100

230 μL; 50 μM probe 9, and 0.125 g/mL spheroplasts. Post-assay spheroplast washing and fluorescence quantitation was performed as described in the Materials and Methods.

Microscopy. Images of post-assay spheroplasts were captured using an Axioskop
2 Plus light microscope equipped with an Axiocam camera, and were processed using
Axiovision software. Fluorescence images were obtained using a Colibri LED light source.
A 2 sec exposure was used in all fluorescence images for comparability. For the NBD-Glc images, brightness was adjusted post-capture, as fluorescence intensity rapidly
decayed on excitation. Identical brightness settings were used for all NBD-Glc fluorescence images for comparability. Excitation wavelengths of 365 nm and 470 nm
were used for probe 9 and NBD-Glc, respectively. Both DIC and fluorescence images

Supporting References

Datsenko, K. A.; Wanner, B. L. Proc. Natl. Acad. Sci. USA 2000, 97, 6640.

Cherepanov, P. P.; Wackernagel, W. Gene 1995, 158, 9.

Chen, W.; Kuo, T. Nucleic Acid Res. 1993, 21, 2260.